How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Commercializing Biomarkers Market
- By Biomarker Type: Diagnostic Biomarkers, Prognostic Biomarkers, Predictive Biomarkers, Pharmacodynamic Biomarkers, Safety Biomarkers
- By Application Area: Oncology, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, Metabolic Disorders
- By End User: Pharmaceutical and Biotechnology Companies, Diagnostic Laboratories, Research Institutes, Contract Research Organizations (CROs), Academic and Clinical Research Centers
- By Technology Platform: Genomics, Proteomics, Metabolomics, Immunoassays, Imaging Biomarkers
- By Product Type: Biomarker Discovery Services, Biomarker Validation Services, Biomarker Diagnostic Kits, Companion Diagnostics, Biomarker Data Analytics Solutions
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Diagnostic Biomarkers leads By Biomarker Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 14 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 303 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.186 →
- 12 Company Profiles 14 players: SWOT & benchmarking p.194 →
Full report · locked preview
Everything inside the Commercializing Biomarkers Market report
A complete, evidence-based study - 12 chapters and 127 sections covering market size, segmentation across 5 axes, regional analysis and 14 company profiles, forecast to 2033.
Segmentation covered
Biomarker Type 5
Application Area 5
End User 5
Technology Platform 5
Product Type 5
Companies profiled
Thermo Fisher Scientific
Roche Diagnostics
Abbott Laboratories
QIAGEN
Bio-Rad Laboratories
Agilent Technologies
PerkinElmer
Danaher Corporation
Illumina
F. Hoffmann-La Roche AG
SomaLogic
Myriad Genetics
+2 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
14 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Thermo Fisher Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Roche Diagnostics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →QIAGEN
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Bio-Rad Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Agilent Technologies
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →PerkinElmer
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Danaher Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Illumina
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →F. Hoffmann-La Roche AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →SomaLogic
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Myriad Genetics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Guardant Health
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Natera
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$8,307M by 2033 · 5.7% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Diagnostic Biomarkers54.8
- Prognostic Biomarkers8.4
- Predictive Biomarkers12.9
- Pharmacodynamic Biomarkers9.8
- Safety Biomarkers14.2
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,759M → $2,625M · 5.1%
Europe$1,226M → $1,961M · 6.0%
Asia Pacific$1,119M → $1,936M · 7.1%
Latin America$692.9M → $1,104M · 6.0%
Middle East and Africa$533.0M → $932.6M · 7.2%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →5.652026
5.672027
5.692028
5.692029
5.692030
5.712031
5.732032
5.752033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Thermo Fisher Scientific19.2
- Roche Diagnostics22.7
- Abbott Laboratories5.3
- QIAGEN8.3
- Bio-Rad Laboratories10.9
- Agilent Technologies5.6
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Biomarker Type22.0%
Application Area19.8%
End User25.9%
Technology Platform16.8%
Product Type15.6%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America30.7
- Europe22.9
- Asia Pacific22.6
- Latin America12.9
- Middle East and Africa10.9
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Thermo Fisher Scientific | 85 | 83 | 84 | 84 | 84 | 84 | 84 |
| Roche Diagnostics | 91 | 90 | 76 | 71 | 81 | 93 | 84 |
| Abbott Laboratories | 88 | 75 | 73 | 68 | 80 | 69 | 76 |
| QIAGEN | 59 | 77 | 65 | 60 | 60 | 69 | 65 |
| Bio-Rad Laboratories | 52 | 62 | 60 | 69 | 69 | 68 | 63 |
| Agilent Technologies | 64 | 63 | 46 | 47 | 60 | 59 | 57 |
| PerkinElmer | 56 | 55 | 58 | 59 | 56 | 43 | 55 |
| Danaher Corporation | 51 | 36 | 59 | 50 | 48 | 37 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Thermo Fisher Scientific
- Roche Diagnostics
- Abbott Laboratories
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific | ✓ | ✓ | ◐ | ✓ | ✓ | ✓ |
| Roche Diagnostics | ◐ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Abbott Laboratories | ✓ | ✓ | − | ◐ | ◐ | − |
| QIAGEN | − | ◐ | − | ◐ | − | ◐ |
| Bio-Rad Laboratories | − | − | ◐ | ◐ | ✓ | ◐ |
| Agilent Technologies | ◐ | ◐ | − | − | ◐ | − |
| PerkinElmer | − | − | − | − | ◐ | ◐ |
| Danaher Corporation | − | − | ◐ | ◐ | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Thermo Fisher Scientific84
2Roche Diagnostics84
3Abbott Laboratories76
4QIAGEN65
5Bio-Rad Laboratories63
6Agilent Technologies57
7PerkinElmer55
8Danaher Corporation47
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Thermo Fisher ScientificRoche Diagnostics
Challenger1
Strong scale, closing on the leaders.
Abbott Laboratories
Contender3
Focused players with pockets of strength.
QIAGENBio-Rad LaboratoriesAgilent Technologies
Niche2
Specialists in a single segment or region.
PerkinElmerDanaher Corporation
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Biomarker Type in North America, then scale across Commercializing Biomarkers Market — a $444M beachhead inside a $8.19B market.
Beachhead (SOM)$444Mobtainable near-term
Serviceable (SAM)$2.96Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Diagnostic Biomarkers
Best fit — highest urgency & budget in Biomarker Type.
Economic buyer80 fit
Prognostic Biomarkers
Strong fit — clear ROI and a fast path to value.
End user69 fit
Predictive Biomarkers
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Biomarker Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application Area & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel28%
Digital / self-serve21%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Biomarker Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Commercializing Biomarkers Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified43%
Sales qualified23%
Evaluation11%
Closed-won8%
$14.2KCAC
$53KLTV
3.7:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Commercializing Biomarkers Market is a durable-growth opportunity — $7.44B by 2033, compounding at 6.1%.
TAM · 2025$4.62Btoday
TAM · 2033$7.44Bforecast
CAGR6.1%2027–2033
Cumulative$53.4Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$7.44BTotal addressable market
SAM$2.63BServiceable available market
SOM$541MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →6.1% CAGR
Demand compounds through 2033, outpacing GDP across Biomarker Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Biomarker Type moving from early to mainstream — durable secular demand.
Consolidation upside
14+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$7.44BLarge & growingTAM by 2033 at 6.1% CAGR
$2.63BServiceable nowreachable with today’s model
$541MBeachhead winobtainable near-term share
14+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$5.81BBear4.0% CAGR
$7.44BBase6.1% CAGR
$9.53BBull8.1% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application Area optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Commercializing Biomarkers Market — a $10.5B market by 2033. Plan: grow share from 8.0% to 14.6%.
Market size · 2033$10.5Btotal addressable
Market CAGR10.9%2027–2033
Target share14.6%from 8.0% today
Revenue ambition$1.54Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.0% | 14.6% | On track |
| Revenue | $863M | $1.54B | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Ahead |
| Gross margin | 35.2% | 40.7% | Behind |
| Customer retention | 87.3% | 96.0% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Biomarker Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application Area capability
A defensible second engine — invest in Application Area to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Biomarker Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application Area
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $229M capacity & capability investment
- Greenlight bolt-on M&A in Application Area
- Authorise North America expansion plan
- Fund R&D program for Biomarker Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Commercializing Biomarkers Market conversation — a $9.21B market you can size, segment and defend in minutes.
Market size · 2033$9.21Btotal opportunity
Growth6.6%CAGR to 2033
Addressable buyers982+accounts in scope
Typical ROI6.2×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Biomarker Type
Goal Grow share in Biomarker Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.2×return on cost, year one
< 4 mopayback period
$62K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
14+players profiled in this market
Coverage includes
Thermo Fisher ScientificRoche DiagnosticsAbbott LaboratoriesQIAGENBio-Rad LaboratoriesAgilent TechnologiesPerkinElmerDanaher Corporation+6 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Commercializing Biomarkers Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Commercializing Biomarkers Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Drugs for Traveler s Diarrhea Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportConstipation Treatment Drug Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportElephantiasis Drug Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportWound cleaning Potion Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportHuman Hepatitis B Immunoglobulin HBIG Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportDiabetic Therapeutic Drugs Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportSterile X Ray Detectable Lap Sponges Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportCooling Paste Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportChronic Kidney Disease Drugs Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportGeneric and Biosimilar Pharmaceuticals Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportDiet Pills Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportHerbal Nutraceutical Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.